Inj, cyclophosphamide, nos
Products billed under this code include Cyclophosphamide.
Payment limit per 5 MG, by effective quarter, 2Q24 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.Products billed under J9075
From the 4Q26 NDC–HCPCS crosswalk. “Limit / pkg” is the 4Q26 payment limit times the billing units in one package.
| Product | Labeler | NDC | Units / pkg | Limit / pkg |
|---|---|---|---|---|
| Cyclophosphamide | Sandoz Inc. | 00781-3233-94 | 100 | $69.20 |
| Cyclophosphamide | Sandoz Inc. | 00781-3244-94 | 200 | $138.40 |
| Cyclophosphamide | Sandoz Inc. | 00781-3255-94 | 400 | $276.80 |
| Cyclophosphamide | Baxter Healthcare Corporation | 10019-0938-01 | 100 | $69.20 |
| Cyclophosphamide | Baxter Healthcare Corporation | 10019-0939-01 | 200 | $138.40 |
| Cyclophosphamide | Baxter Healthcare Corporation | 10019-0942-01 | 400 | $276.80 |
| Cyclophosphamide | Baxter Healthcare Corporation | 10019-0943-01 | 100 | $69.20 |
| Cyclophosphamide | Baxter Healthcare Corporation | 10019-0944-01 | 200 | $138.40 |
| Cyclophosphamide | Baxter Healthcare Corporation | 10019-0945-01 | 400 | $276.80 |
| Cyclophosphamide | Baxter Healthcare Corporation | 10019-0955-01 | 100 | $69.20 |
Show all 41 products
| Product | Labeler | NDC | Units / pkg | Limit / pkg |
|---|---|---|---|---|
| Cyclophosphamide | Baxter Healthcare Corporation | 10019-0956-01 | 200 | $138.40 |
| Cyclophosphamide | Baxter Healthcare Corporation | 10019-0957-01 | 400 | $276.80 |
| Cyclophosphamide | Northstar RxLLC | 16714-0857-01 | 200 | $138.40 |
| Cyclophosphamide | Northstar RxLLC | 16714-0858-01 | 400 | $276.80 |
| Cyclophosphamide | Northstar RxLLC | 16714-0859-01 | 100 | $69.20 |
| Cyclophosphamide | Sagent Pharmaceuticals | 25021-0247-50 | 100 | $69.20 |
| Cyclophosphamide | Sagent Pharmaceuticals | 25021-0248-51 | 200 | $138.40 |
| Cyclophosphamide | Sagent Pharmaceuticals | 25021-0249-51 | 400 | $276.80 |
| Cyclophosphamide | XGen Pharmaceuticals DJB, Inc. | 39822-0250-01 | 100 | $69.20 |
| Cyclophosphamide | XGen Pharmaceuticals DJB, Inc. | 39822-0255-01 | 200 | $138.40 |
| Cyclophosphamide | XGen Pharmaceuticals DJB, Inc. | 39822-0260-01 | 400 | $276.80 |
| Cyclophosphamide | FreseniUS Kabi USA, LLC | 65219-0131-20 | 200 | $138.40 |
| Cyclophosphamide | FreseniUS Kabi USA, LLC | 65219-0133-20 | 400 | $276.80 |
| Cyclophosphamide | FreseniUS Kabi USA, LLC | 65219-0135-20 | 100 | $69.20 |
| Cyclophosphamide | BluePoint Laboratories | 68001-0442-26 | 100 | $69.20 |
| Cyclophosphamide | BluePoint Laboratories | 68001-0443-27 | 200 | $138.40 |
| Cyclophosphamide | BluePoint Laboratories | 68001-0444-32 | 400 | $276.80 |
| Cyclophosphamide | Bluepoint Laboratories | 68001-0694-27 | 100 | $69.20 |
| Cyclophosphamide | Bluepoint Laboratories | 68001-0695-32 | 200 | $138.40 |
| Cyclophosphamide | BluePoint Laboratories | 68001-0696-32 | 400 | $276.80 |
| Cyclophosphamide | Amneal Pharmaceuticals, LLC | 70121-1238-01 | 100 | $69.20 |
| Cyclophosphamide | Amneal Pharmaceuticals, LLC | 70121-1239-01 | 200 | $138.40 |
| Cyclophosphamide | Amneal Pharmaceuticals, LLC | 70121-1240-01 | 400 | $276.80 |
| Cyclophosphamide | Civica, Inc. | 72572-0083-01 | 400 | $276.80 |
| Cyclophosphamide | Civica, Inc. | 72572-0085-01 | 200 | $138.40 |
| Cyclophosphamide | Civica, Inc. | 72572-0087-01 | 100 | $69.20 |
| Cyclophosphamide | Northstar RxLLC | 72603-0104-01 | 100 | $69.20 |
| Cyclophosphamide | Northstar RxLLC | 72603-0326-01 | 200 | $138.40 |
| Cyclophosphamide | Long Grove Pharmaceuticals, LLC | 81298-8110-01 | 100 | $69.20 |
| Cyclophosphamide | Long Grove Pharmaceuticals, LLC | 81298-8112-01 | 200 | $138.40 |
| Cyclophosphamide | Long Grove Pharmaceuticals, LLC | 81298-8114-01 | 400 | $276.80 |
Every quarter
| Quarter | Payment limit | Change | Billing unit | Description | Source file |
|---|---|---|---|---|---|
| 4Q26 | $0.692 | +$0.117 | 5 MG | Inj, cyclophosphamide, nos | v1, posted September 17, 2026 |
| 3Q26 | $0.575 | −$0.198 | 5 MG | Inj, cyclophosphamide, nos | v1, posted September 15, 2026 |
| 2Q26 | $0.773 | +$0.188 | 5 MG | Inj, cyclophosphamide, nos | v1, posted September 15, 2026 |
| 1Q26 | $0.585 | +$0.104 | 5 MG | Inj, cyclophosphamide, nos | v1, posted September 15, 2026 |
| 4Q25 | $0.481 | −$0.143 | 5 MG | Inj, cyclophosphamide, nos | v1, posted September 8, 2026 |
| 3Q25 | $0.624 | −$0.175 | 5 MG | Inj, cyclophosphamide, nos | v1, posted March 10, 2026 |
| 2Q25 | $0.799 | −$0.077 | 5 MG | Inj, cyclophosphamide, nos | v1, posted March 10, 2026 |
| 1Q25 | $0.876 | −$0.134 | 5 MG | Inj, cyclophosphamide, nos | v1, posted December 19, 2025 |
| 4Q24 | $1.01 | −$0.096 | 5 MG | Inj, cyclophosphamide, nos | v1, posted June 11, 2025 |
| 3Q24 | $1.106 | +$0.188 | 5 MG | Inj, cyclophosphamide, nos | v1, posted June 11, 2025 |
| 2Q24 | $0.918 | – | 5 MG | Inj, cyclophosphamide, nos | v1, posted March 11, 2025 |
“Change” is the difference from the previous quarter, shown only when both quarters have a payment limit and the billing unit is the same. “vs. last quarter” and “vs. a year ago” follow the same rule.
CMS source files
- 4Q26: 2026-09-17_october-2026-medicare-part-b-payment-limit-files-final.zipposted September 17, 2026
- 4Q26: 2026-09-17_october-2026-ndc-hcpcs-crosswalk-final.zipposted September 17, 2026
- 3Q26: 2026-09-15_july-2026-medicare-part-b-payment-limit-files.zipposted September 15, 2026
- 2Q26: 2026-09-15_april-2026-medicare-part-b-payment-limit-files-final-file.zipposted September 15, 2026
- 1Q26: 2026-09-15_january-2026-medicare-part-b-payment-limit-files.zipposted September 15, 2026
- 4Q25: 2026-09-08_october-2025-asp-pricing-final-file.zipposted September 8, 2026
- 3Q25: 2026-03-10_july-2025-asp-pricing-file.zipposted March 10, 2026
- 2Q25: 2026-03-10_april-2025-asp-pricing-file.zipposted March 10, 2026
- 1Q25: 2025-12-19_january-2025-asp-pricing-file-03-11-25-final-file.zipposted December 19, 2025
- 4Q24: 2025-06-11_october-2024-asp-pricing-file.zipposted June 11, 2025
- 3Q24: 2025-06-11_july-2024-asp-pricing-file.zipposted June 11, 2025
- 2Q24: 2025-03-11_april-2024-asp-pricing-file.zipposted March 11, 2025